The REVITALYZ study met its primary endpoint, demonstrating significant improvements in excessive daytime sleepiness for adults with idiopathic hypersomnia treated with once-nightly LUMRYZ.
During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.
A study suggests that a way to improve the salty taste of once-nightly sodium oxybate could be found in patients’ refrigerators.
Avadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.
Read More
Patient usage of Lumryz in increased 70% in Q1, while Avadel plans to expand into pediatric treatment and launch a phase 3 trial in idiopathic hypersomnia.
Read More
A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.
Read More
Avadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
Read More
Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read More
Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.
Read More
Avadel Pharmaceuticals announced new and encore data abstracts emphasizing the clinical benefit of Lumryz and patient preference for a once-at-bedtime narcolepsy treatment option.
Read More
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read More
Avadel aims to expand the potential of Lumryz with a supplemental New Drug Application filing planned in the second half of 2023 for Lumryz in the pediatric narcolepsy population.
Read More
The study, funded by Avadel Pharmaceuticals, describes clinician preferences among oxybate treatments for narcolepsy.
Read More
After receiving FDA approval last month, Lumryz, a once-nightly formulation of sodium oxybate, is now commercially available for adults with narcolepsy.
Read More
Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.
Read More
The authorization allows the company to shorten the time to product availability following an anticipated final approval decision from the FDA.
Read More
If approved, Avadel expects once-at-bedtime Lumryz to be the treatment of choice for patients with narcolepsy-related excessive daytime sleepiness or cataplexy.
Read More
Two of the three narcolepsy comorbidities are well documented, but the third is likely new information for many physicians and patients.
Read More